Department of Ear Nose and Throat, Oncology Training and Research Hospital, Onkoloji Hastanesi, Demetevler, 06200, Ankara, Turkey.
Department of Ear Nose and Throat, Oncology Training and Research Hospital, Ankara, Turkey.
Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3639-3644. doi: 10.1007/s00405-021-07206-5. Epub 2022 Feb 8.
The correlation of CSE1L (human chromosomal segregation 1-like) staining intensity with disease-free survival, disease recurrence and development of distant metastases in Advanced Laryngeal Tumors.
Specimens of patients with advanced glottic larynx cancer (T3, T4) were evaluated for nuclear CSE1L staining intensity. According to mild, moderate and severe CSE1L staining, patients were compared in terms of disease-free survival, disease recurrence and development of distant metastases.
17 of the 57 patients died within 5 years, distant metastases developed in 5 patients, and recurrence in 5 patients. Of the 17 patients who died within 5 years, 10(%59) showed severe staining with CSE1L, 6 (%35) showed moderate staining, and only 1 (%6) patient showed mild staining. 4 (%80) out of 5 patients who developed distant metastases were those with moderate staining with CSE1L. Metastases did not develop in any patient who stained poorly with CSE1L. 2 (%40) of the 5 patients who developed relapse were patients with severe staining with CSE1L, while 3 (%60) were patients with moderate staining with CSE1L. No recurrence was observed in any patient with mild staining with CSE1L.
CSE1L will help in demonstrating the increased risk of distant metastasis, increased recurrence probability and shortened life expectancy of advanced laryngeal carcinoma.
研究 CSE1L(人类染色体分离 1 样)染色强度与晚期喉癌患者无病生存、疾病复发和远处转移发展的相关性。
评估了 57 例晚期声门型喉癌(T3、T4)患者的核 CSE1L 染色强度。根据 CSE1L 染色的轻度、中度和重度,比较了患者在无病生存、疾病复发和远处转移发展方面的差异。
57 例患者中有 17 例在 5 年内死亡,5 例发生远处转移,5 例复发。在 5 年内死亡的 17 例患者中,10 例(59%)表现为 CSE1L 染色重度,6 例(35%)为中度,仅有 1 例(6%)为轻度。发生远处转移的 5 例患者中,4 例(80%)为 CSE1L 中度染色。CSE1L 染色差的患者均未发生转移。复发的 5 例患者中,2 例(40%)为 CSE1L 染色重度,3 例(60%)为 CSE1L 染色中度。CSE1L 染色轻度的患者均未复发。
CSE1L 有助于显示晚期喉癌远处转移风险增加、复发概率增加和预期寿命缩短。